Xinji and Baiji Shenzhou have reached a global strategic cooperation in the field of immune tumor

Source: antibody circle 2017-07-06 sumit, New Jersey, USA and Beijing, China -- (Business Wire) - (US business information) -- new base company (NASDAQ Stock Code: celg) and Baiji Shenzhou Co., Ltd (NASDAQ Stock Code: bgne) announced a strategic cooperation to jointly develop and commercialize anti programmed cell death protein (PD-1) inhibitors Bgb-a317, used to treat solid tumors The cooperation will cover a number of countries and regions outside the United States, Europe, Japan and Asia At the same time, Baiji Shenzhou still has the global authorization for the development and commercialization of bgb-a317 for the treatment of hematological malignancies Baekje will also have a license to develop and commercialize bgb-a317 in Asia (except Japan) for the treatment of solid tumors In addition, Baiji Shenzhou will take over the operation of Xinji company in China and have the exclusive authorization of Xinji company's approved products in China, including atraxane ® paclitaxel for injection (albumin binding type), refumex ® (lenalidomide) and vidaza ® azacytidine for injection Bgb-a317 is a leading PD-1 inhibitor in clinical trials More than 500 cancer patients have participated in the trials Preliminary clinical data showed that bgb-a317 was well tolerated and had antitumor activity in a series of solid tumor fields Bgb-a317 has high affinity and specificity for PD-1 Different from the currently approved PD-1 antibody, bgb-a317 has been optimized in FC area through bioengineering technology, which can reduce the probability of interaction with other immune cells, thus reducing the impact on T cell function Bgb-a317 is being developed as a monotherapy and a combination of other therapies for solid tumors At present, two key researches of bgb-a317 have been carried out in China, and it is planned to launch in 2018 Xinji and Baiji Shenzhou will carry out global cooperation to jointly develop bgb-a317 In addition, Baiji Shenzhou still has the authorization for bgb-a317 to be used in the field of Hematology and development in combination with other product compounds "The acquisition of bgb-a317 will significantly accelerate the development of T-cell 'immunocheckpoint' inhibitors in the field of solid tumors, and create more opportunities to benefit patients with solid tumors around the world," said Mark alles, CEO of newbase In addition, the project will also become the PD-L1 function in the field of hematological malignancy under development Gamma Part of the development project The Chinese market is very important for new kiew This cooperation with Baiji Shenzhou will further optimize the R & D, production and long-term commercial development potential of Xinji, and better base on the development in China " John v oyler, co-founder and CEO of Baiji Shenzhou, said: "for Baiji Shenzhou, the strategic partnership with Xinji is an important transformation for us, which helps us to carry out the commercialization transformation, so as to prepare for the future listing of products under research In China, some compounds in Baiji Shenzhou have entered the critical test stage This strategic cooperation is very consistent with the corporate mission and key disease areas of Baiji Shenzhou We believe that this partnership will help Baiji Shenzhou and Xinji form an alliance to jointly practice the vision of providing innovative therapies and improving the quality of life of patients in China and around the world " Baiji Shenzhou will take over the operation of Xinji in China and be responsible for the commercialization of Xinji's approved products in China, including atraxane ® paclitaxel for injection (albumin binding type), refumex ® (lenalidomide) and vidaza ® azacytidine for injection In addition, Baiji Shenzhou will be authorized by cc-122 in China, and the relevant terms and conditions are consistent with the products of other new base companies that have been listed in China Cc-122 is the next generation of innovative drug (celmod), which is currently in the stage of research and development for the treatment of lymphoma and HCC Baiji Shenzhou plans to further expand its production and marketing team in China to prepare for the future launch of bgb-a317 and other innovative therapies Xinji will maintain a new branch in China, including strategic and R & D departments, focusing on the long-term business strategy, Registration Affairs and clinical R & D of innovative therapies in China in the future NSK will continue to support the rife America risk management project Upon completion of the acquisition, Baiji Shenzhou will receive an advance payment of about $263 million In addition, Xinji will purchase 327 million or 5.9% common shares of Baiji Shenzhou for $4.58 per share The price of US $59.55 per share is equivalent to a 35% premium to the volume weighted average price of American Depository Receipts in the previous 11 trading days in baichi Baichi can receive milestone payments of up to $980 million (including R & D, registration and sales) and bgb-a317 sales royalties The deal has been approved by the board of directors of SUNKEY and Baiji Both parties are expected to complete this transaction in the third quarter of 2017, and the specific completion time will depend on the expiration or end of the waiting period specified in other applicable provisions such as the anti-monopoly law Bgb-a317 is not currently approved in any country Bgb-a317 bgb-a317 is a kind of humanized monoclonal antibody in clinical trial, which belongs to a tumor immune agent called "immunocheckpoint" inhibitor The mechanism of bgb-a317 is binding with PD-1 receptor on the cell surface, which is an important immunosuppressive molecule, which can inhibit the activation of T cells and thus reduce the role of the immune system Bgb-a317 has high affinity and specificity for PD-1 Different from the currently approved PD-1 antibody, bgb-a317 has been optimized in Fc region by bioengineering technology, which can reduce the probability of negative interaction with other immune cells Bgb-a317 is being developed as a monotherapy and a combination of other therapies for different types of tumors About celgene, a global biopharmaceutical company, headquartered in sumit, New Jersey, USA, is mainly engaged in the R & D and commercialization of innovative therapies related to cancer and inflammatory diseases through the next generation solutions in the fields of protein homeostasis, immunooncology, epigenetics, immunology and neuroinflammation For more information, please visit the company's website and follow celgene, @ celgene, pinterest, LinkedIn, Facebook, and Youtube on the social media platform Baiji Shenzhou is a global R & D-based biotech company focusing on molecular targeting and immunotherapy At present, Baiji Shenzhou has more than 400 employees in mainland China, the United States and Australia, and its research product line includes new small molecule targeting and monoclonal antibody anti-cancer drugs Baiji Shenzhou is committed to creating the optimal combination of drugs to bring lasting and far-reaching impact on the life of cancer patients.